Difference between revisions of "Envoplakin"
m |
|||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
− | |||
− | |||
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
Line 46: | Line 44: | ||
| | | | ||
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Epidermal transglutaminase|*]] | [[Category:Epidermal transglutaminase|*]] |
Latest revision as of 11:09, 10 March 2015
Envoplakin | |
---|---|
Substrate peptide name | Envoplakin |
Synonyms | - |
Determination type | In vitro |
Source | Homo sapiens |
Subcellular localization | Cornified envelope |
Swissprot ID | Q92817 |
Reactive glutamines | Q1970, Q1973 |
Reactive lysines | Not determined yet |
Substrate sequence | SEELAQLLQDESSF |
Structure | No available crystal structure |
Surface accessibility | |
Disorder prediction | IUPred |
Reference | PMID:9482839 |
Notes | |